30/06/2023
Pharmena sold its dermocosmetic business
Pharmena SA sold its dermocosmetic business to Laboratorio Genove, an international company based in Barcelona that is specialized in dermo-cosmetic products. As part of the transaction, Pharmena sold all shares of Dermena Lab and an organized part of the enterprise related to dermocosmetic business. After the sale of the dermocosmetic business, Pharmena has a plan to continue its activities in the field of sales of dietary supplements, present a potential candidate for an innovative 1-MNA-based products and start work on other projects based on this active substance.
01/10/2016
Eagles of the “Wprost” weekly
Eagles of the “Wprost” weekly Category: "The most dynamically developing companies in the Łódź Voivodeship"
23/03/2016
Diamond of the Forbes Magazine
Pharmena SA was awarded among companies with revenue ranging from PLN 5 million to 50 million.
20/10/2015
Łódź Voivodeship Special Award for 2015
Granted by voivodeship governor and voivodeship marshal for investing in researches, development scientific description and implementation of innovative products.
24/07/2015
Pharmena SA is the market innovation leader of 2015
Within the scope of the national promotional programme organised by the editorial office of Strefa Gospodarki, PHARMENA SA was awarded the title of Market Innovation Leader 2015 - Quality, Creativity, Effectiveness". The title granted to the Company is an objective confirmation of the innovativeness and competitiveness of products offered by the Company. It also stands as a reliable guarantee ensuring market reliability, consistence and stability of the company.
26/02/2015
Pharmena among “Forbes Diamonds 2015”
Pharmena SA has been placed, for the first time, in the prestigious circle of FORBES DIAMONDS 2015. The ranking of the monthly magazine Forbes assesses commercial and production companies that have been increasing their values at the fastest rate. In the Lodz region, there were 84 companies honoured with the title "Forbes Diamond” in three categories, according to the amount of their income. Pharmena SA took the 4th place in the Lodz region and 88th place in Poland in the category of companies whose income ranges from 5 to 50 million PLN.
30/11/2012
Company’s anniversary celebrations
The post-industrial interiors of andel's hotel restaurant in Łódź hosted a ceremonial gala celebrating 10th anniversary of the Pharmena company. The company founders and those who had a significant contribution to its success received commemorative statuettes from the President of the Board. All present guests had a chance to recollect the company’s beginnings and hear about its future plans. The event’s cordial atmosphere was intensified by Stanisław Soyka’s performance.
27/11/2012
Pharmena SA on a conference held by the Association of Individual Investors
At the invitation of the Association of Individual Investors in Poland, Pharmena SA was a guest on a “Professional Investor” conference, which took place in Jachranka (near Warsaw) on 23rd-25th November 2012. During the “Workshops of Practical Knowledge”, which concentrated on practical expertise on stock exchange investments, the Company’s President of the Board – Konrad Palka talked about the idea of commercialisation of biotechnological projects. The conference “Professional Investor” is the second largest meeting of individual investors in Poland.
17/06/2011
Company’s HQ address change
The Company Pharmena SA has moved its headquarters. Currently, the Company’s office is situated in the very centre of Łódź.
06/10/2010
Pharmena SA in NC LEAD segment
On 30th September 2010, the Management Board of Warsaw Stock Exchange S.A. announced a list of companies, which were qualified to NewConnect Lead segment, and Pharmena SA was one of them. This is yet another nomination of the Issuer for the NewConnect market segment of leading companies.
25/08/2008
PHARMENA’S debut at New Connect
On August 25, 2008, PHARMENA S.A. joined the Exchange Members listed at the Warsaw Stock Exchange. In the alternative turnover system of New Connect, 5.73 million of series A shares and 524,260 series B shares are listed. The Company is going to allocate the gained funds to further support research in the United States and Canada, as well as marketing of the actual products.
04/06/2008
Pharmena in New Connect – New issue of the Company shares
The Company has issued new Series B shares to the value of PLN 13.6 million – as part of its private placement. Almost 100% of the issue has been taken by financial institutions. Next Pharmena intends to enter on the Stock Exchange in the New Connect market. The successful issue of the shares was aimed at raising extra funds for financing further research in the United States and Canada and marketing the current products.
13/04/2008
Transformation of Pharmena Co. Ltd. into Pharmena Joint-Stock Co.
Due to the planned private placement and entering the Company in the Alternative Trading System New Connect market organized by the Warsaw Stock Exchange S.A. on April 17, 2008, Pharmena has transformed itself as a legal entity – from a limited liability company into a joint-stock company.
28/11/2007
PHARMENA – Winner of the Lodz Region Governor’s Business Award
Regional business leaders awarded The Lodz Region Governor, Witold Gwiazda, has given business awards to the region’s best companies. Nine managers received statuettes designed by a Lodz-based sculptor Kazimierz Karpiński, and three others were given occasional diplomas. The Lodz Region Governor’s Business Award is the only regional state award, of honourable nature, and this year’s was its fourth consecutive edition. In their brand and advertising materials, the laureates may use the title „Winner of the Lodz Region Governor’s Business Award 2007”. The companies awarded with diplomas may use the title: „Honoured in the Lodz Region Governor’s Business.
12/10/2007
Launch Of Clinical Studies For New Dyslipidemia Agent In North America
Clinical studies of a new drug candidate for the treatment of dyslipidemia are initiated in North America by Pharmena's partner.
03/09/2007
First Polish Drug in the USA
In the second half of 2007, in the USA and Canada there will be launched another stage of clinical studies of an innovative drug for dislipidemia – lipid profile disorder (cholesterol and triglycerides). Pilot basic research has been carried out in Poland. The drug patent holder is PHARMENA, which company has transferred the know-how to Pharmena North America Inc., established in August of 2005. The licence agreement, based on the patent held by the Lodz-based company, provides for relevant studies to be carried out in the USA and Canada, and possibly for the drug to be commercialised. If these studies are successful, there is a chance that this will be the first drug, developed by the Polish scientific thought, to be registered in the USA. SHORTCUTS Company Research Products News Investor relations Contact WHAT WE DO? New product development Drug research Dietary supplement PRODUCTS Endotelio CONTACT PHARMENA S.A. ul. Gdańska 47/49 90-729 Łódź +48 728 510 293 biuro@pharmena.eu
06/12/2006
Pharmena North America Inc. Has Attracted A New Investor
In November of 2006, Domain Associates, L.L.C, a leading Venture capital firm, invested in Pharmena North America Inc. Domain Associates focuses on investing in promising enterprises in the biotechnology and pharmaceutical sectors. Since its formation in 1985, the fund has participated in the growth and success of more than 180 companies.
03/08/2005
Pharmena North America Inc. Formation
In August, PHARMENA formed Pharmena North America Inc. (PNAI), headquartered in Boston, to conduct clinical development in the USA and Canada. PNAI’s objective is to develop and market in North America product candidate produced from research and development activities at PHARMENA.
20/05/2005
PHARMENA - Modern Technology Leader
The New Technologies Institute of Lodz, supporting entrepreneurship and Lodz’s promotion as a city of new technologies, has organised the „Modern Technology Leader” Competition. The event’s objective is to distinguish and award companies that apply modern technologies and innovative solutions. The competition has three categories: small, medium, and large businesses. The chapter awarded our Company, granting PHARMENA the " Modern Technology Leader" title in the small entrepreneurs category.
25/11/2004
MNA+ Therapeutic Function Discovery Awarded at the 53rd „Brussels Eureka-2004
The "MNA+ therapeutic function discovery" was presented at the 53rd „Brussels Eureka-2004" World Exhibition of Innovation, Research, and New Technologies „Brussels Eureka-2004". The exhibition was held between 16 - 21 November in Brussels. The invention authors were awarded with the silver medal. Also, they received a special mention for creative courage.
10/09/2003
1-Methylnicotinamide Chloride Research Findings Unveiled at the 4th Technology Congress
Research findings regarding 1-Methylnicotinamide chloride were unveiled in a plenary lecture on 10 September, 2003 at the 4th Chemical Technology Congress in Lodz. The lecturer was Professor Jerzy Gębicki. The congress in Lodz was attended by more than 500 scientists.